TRIL Trillium Therapeutics Inc.

6.78
+1.01  (+18%)
Previous Close 5.77
Open 6.69
Price To Book -75.33
Market Cap 565,699,524
Shares 82,683,425
Volume 6,384,552
Short Ratio
Av. Daily Volume 2,354,313
Stock charts supplied by TradingView

NewsSee all news

  1. Trillium Therapeutics Provides Update on the Phase I Dose Escalation Study of Its CD47 Blocker TTI-622 at the ASCO20 Virtual Scientific Program

    Dosing has progressed through first five cohorts up to 4 mg/kg dose levelStrong safety profile, with no dose-limiting toxicities observedMonotherapy activity (1 CR and 1 PR) observed in DLBCL patientsFurther dose

  2. Trillium Therapeutics Reports First Quarter 2020 Financial and Operating Results

    CAMBRIDGE, Mass., May 15, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ("Trillium" or the "Company") (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of

  3. Trillium Therapeutics to Present Data on CD47 Blocker TTI-622 in Advanced Relapsed or Refractory Lymphoma at the ASCO20 Virtual Scientific Program

    CAMBRIDGE, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ("Trillium" or the "Company") (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of

  4. Trillium Therapeutics Announces "At-The-Market" Equity Program

    CAMBRIDGE, Mass., May 06, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ("Trillium" or the "Company") (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of

  5. TRILLIUM THERAPEUTICS PROVIDES BUSINESS UPDATE IN RESPONSE TO THE COVID-19 PANDEMIC

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 trial ongoing. ORR 18-29%. Update due mid-2020 and at ASH December 2020.
TTI-621-01
Diffuse Large B-cell Lymphoma (DLBCL), Cutaneous T-cell lymphoma (CTCL)
Phase 1 trial ongoing.
TTI-621-02
Solid tumors
Phase 1a/b update at May 29, 2020. 2/19 objective responses.
TTI-622
Refractory lymphoma or multiple myeloma

Latest News

  1. Trillium Therapeutics Provides Update on the Phase I Dose Escalation Study of Its CD47 Blocker TTI-622 at the ASCO20 Virtual Scientific Program

    Dosing has progressed through first five cohorts up to 4 mg/kg dose levelStrong safety profile, with no dose-limiting toxicities observedMonotherapy activity (1 CR and 1 PR) observed in DLBCL patientsFurther dose

  2. Trillium Therapeutics Reports First Quarter 2020 Financial and Operating Results

    CAMBRIDGE, Mass., May 15, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ("Trillium" or the "Company") (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of

  3. Trillium Therapeutics to Present Data on CD47 Blocker TTI-622 in Advanced Relapsed or Refractory Lymphoma at the ASCO20 Virtual Scientific Program

    CAMBRIDGE, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ("Trillium" or the "Company") (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of

  4. Trillium Therapeutics Announces "At-The-Market" Equity Program

    CAMBRIDGE, Mass., May 06, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ("Trillium" or the "Company") (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of

  5. TRILLIUM THERAPEUTICS PROVIDES BUSINESS UPDATE IN RESPONSE TO THE COVID-19 PANDEMIC

  6. Trillium Therapeutics Reports Annual Financial and Operating Results

    CAMBRIDGE, Mass., March 10, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial

  7. Trillium Therapeutics Responds to Market Activity

    CAMBRIDGE, Mass., Feb. 28, 2020 (GLOBE NEWSWIRE) -- At the request of IIROC ("Investment Industry Regulatory Organization of Canada"), Trillium Therapeutics Inc. (the "Company") (TSX:TRIL) wishes to confirm

  8. Trillium Therapeutics Announces Changes to Its Board of Directors

    Paul Walker of New Enterprise Associates is appointed to the Board of Directors CAMBRIDGE, Mass., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ("Trillium" or the "Company") (TSX:TRIL), a clinical stage

  9. Trillium Closes US$117 Million Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares

    CAMBRIDGE, Mass., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ("Trillium" or the "Company") (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of

  10. Trillium Announces Pricing of US$101,700,000 Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares

    CAMBRIDGE, Mass., Jan. 23, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ("Trillium" or the "Company") (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of

  11. Trillium Announces Proposed Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares

    CAMBRIDGE, Mass., Jan. 22, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ("Trillium" or the "Company") (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of

  12. Trillium Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

    CAMBRIDGE, Mass., Jan. 16, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ("Trillium" or the "Company") (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of

  13. Trillium Therapeutics Provides Update on Its TTI-621 and TTI-622 CD47 Programs

    Intravenous TTI-621 dose escalation under initial dose limiting toxicity (DLT) criteria now completed – confirms TTI-621 monotherapy activity (including complete responses) in hematologic malignancies at doses up to 0.5

  14. Trillium Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    TORONTO, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ("Trillium" or the "Company") (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer,

  15. Trillium Granted 180-Day Extension by NASDAQ to Regain Compliance With Minimum Bid Price Rule

    TORONTO, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (TSX:TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has

  16. Trillium Therapeutics Appoints Jan Skvarka as President and Chief Executive Officer

    TORONTO, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced the appointment of Mr.

  17. Trillium Therapeutics To Present At Investor Conference

    TORONTO, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company